Why Dr. Rod Rohrich Is Considered One Of The Best Plastic Surgeons In The Nation

Dallas, Texas-based Plastic Surgeon Rod J. Rohrich is considered one of the best in his industry. He has written many textbooks and research papers about rhinoplasty (aka “nose jobs”), revision rhinoplasty, breast surgery, and facelifts. He has also taught these procedures for many years at UT Southwestern Medical Center as the professor of plastic surgery. He is a board certified plastic surgeon and is a member of both the American Society of Plastic Surgeons and the American Society for Aesthetic Plastic Surgery. D Magazine has named him one of the top doctors since 1996.

Dr. Rod Rohrich is internationally known for his skill at rhinoplasty. This type of procedure can change the appearance, shape, and even function of a nose. He also does revision rhinoplasty which not many plastic surgeons are able to do. This is a very complicated surgery which corrects issues for people who have previously had a nose job. What makes this so complex is that the nasal structures are very delicate and since they’ve already been worked on once a second time can go really wrong if it is not done perfectly.

He has been doing breast lift surgery and breast augmentation surgeries for over 20 years. Dr. Rod Rohrich says that each situation is different and calls for different types of implants and the materials they are made of. This can include both saline breast implants and silicone gel breast implants depending on what will work best for each patient. In order to help women who have had a mastectomy he co-founded a nonprofit called the AiRS Foundation which helps to pay for the cost of this procedure.

He also performs facelift surgery on patients. Additionally Dr. Rod Rohrich has contributed by writing research papers about this type of procedure and teaching about it as well. He has been helping to reverse facial aging for 18 years.

Follow Rohrich on Instagram

Felipe Montoro Jens Reports on IDB’s Special Meeting

Felipe Montoro Jens has served in many organizations, and currently, he is the CEO of EnergiparCaptação S.A. He recently made a report about the special meeting that was held on March 24, in Mendoza City, Argentina, by all the governors of the Inter-American Development Bank (The IDB). Learn more about Felipe Montoro Jens at terra.com

The Latin American Challenge

He revealed that from the viewpoint of the bank’s president, Luis Alberto Moreno, the Latin American challenge is the enhanced connectivity that is there between various countries. It also comprises the convergence of infrastructure. According to Mr. Moreno, it is impossible for the region to register any development and growth without the two. He also added that investments alone are not enough to overcome the various obstacles that hinder progress.

Adapting New Social Demands

As Felipe Montoro Jens reported, the IDB’s president said that the bank had embraced the new social needs. This has enabled them to reinforce policies that revolve around factors like gender equality and environmental sustainability whenever they are executing their various projects.

Public-Private Partnerships

Montoro also said that Dyogo Oliveira, who was then the Minister of Planning Development and Management, talked about Brazil’s public-private partnerships that they have made for public works. The minister also mentioned the efforts of the Brazilian government to develop the field of infrastructure and financing. He made it clear that all those actions are perfectly in line with the bank and other agencies that the country is involved in.

Another revelation that Mr. Montoro made is that the Inter-American Development Bank has loaned around $ 12.9 billion to Brazil. This is 20% more than the amount they received in 2016.

In the report, Felipe Montoro Jens revealed the various problems that prevent infrastructural development in Latin America. He also stated the multiple steps that the IDB is making to enhance growth in countries like Brazil.



Dr. Clay Siegall is the CEO and Founder of Seattle Genetics. Seattle Genetics is an organization dealing with biotech, and it works in the advancement of focused treatment drugs for infection types which have not significantly seen mortality changes in years. Dr. Clay has a zoology B.S which he obtained from Maryland University and a genetics Ph.D. from the University of George Washington.

Since 1998 the time he established Seattle Genetic, Siegall has developed the company to the center of the industry of targeted therapy, coming up with the most recent conjugated antibody drugs that are FDA-approved, and which have several indications approvals. The other development is the significant pipeline of over twenty drugs and a thread of critical associations with manufacturers of drugs involving, Genentech, Pfizer, Bayer and numerous others.

In the leadership of Clay Siegall, Seattle Genetics has moved from a minor startup with only a few groups of specialists to an influential and prominent player in the research space of cancer. Dr. Clay has massive plans for the future of the company. With a consistently growing rundown of medications in the advancement pipeline and a regularly expanding number of promising signs for the organization’s current portfolio of drugs, Seattle Genetics is all round placed to match in the future of the industry of drug improvement with substantial authority.

Dr. Clay trusts that cancer treatment old-guard, to be specific, foundational chemotherapies, are bound to be outdated very soon. As the efficacy and value of focused treatments move towards becoming evident in some years to come, Clay believes the procedures of the past will be replaced by the undeniably more effective and tolerable targeted drugs.

Clay Siegall has always been interested in, technological power, medicine, and the urge to overcome disease, this is the reason he got inspired to start his company. Also, he is interested in the restoration of health to those who might find themselves at the brink of death. Clay makes cash through selling proprietary drugs at Seattle Genetics, and the company became profitable a decade after IPO.

The organization has dedicated sales workers, who have solid foundations in biotech and know the business and products inside out which is extremely imperative. The sale persons are essential since they assist in closing some important deals that benefit the organization.